Detail of "1716-12-7"

Reference

Inhibition of DNA Methylation and Histone Deacetylation Prevents Murine Lung Cancer

Inhibition of DNA Methylation and Histone Deacetylation Prevents Murine Lung Cancer. Belinsky, Steven A.; Klinge, Donna M.; Stidley, Christine A.; Issa, Jean-Pierre; Herman, James G.; March, Thomas H.; Baylin, Stephen B. (Lovelace Respiratory Research Institute, Albuquerque, NM 87108, USA). Cancer Research, 63(21), 7089-7093 (English) 2003 American Association for Cancer Research. CODEN: CNREA8. ISSN: 0008-5472. 9037-42-7 and 1716-12-7 which are cas registry numbers are also used here. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) Section cross-reference(s): 4 Disruption of one allele for the cytosine-DNA methyltransferase 1 (DNMT1) gene in mice with a germ-line mutation in a tumor suppressor gene was shown previously to reduce tumor formation in juvenile animals. This effect is now reproduced in our studies of mature mice where this genetic DNMT1 redn. leads to a 50% decrease in tobacco carcinogen-induced lung cancer and a similar redn. in DNMT activity in type II pneumocytes that give rise to the tumors. Short-term treatment of DNMT wild-type female mice with low doses of the demethylating agent 5-aza-2'-deoxycytidine decreased the incidence of neoplasms by 30%. Importantly, when 5-aza-2'-deoxycytidine was combined with the histone deacetylase inhibitor sodium phenylbutyrate, lung tumor development was significantly reduced by >50%; no effect was seen with phenylbutyrate alone. This identical combination of inhibitors also acts synergistically to cause re-expression of densely hypermethylated and transcriptionally silenced tumor suppressor genes in human cancer cells. Thus, redn. in DNMT and histone deacetylase activities that likely block epigenetically mediated gene silencing might provide a novel clin. strategy to help prevent the leading cause of cancer death in the United States. .

Histone deacetylase inhibitors and pharmaceutical compositions containing them, to treat radiation cutaneous syndrome

Histone deacetylase inhibitors and pharmaceutical compositions containing them, to treat radiation cutaneous syndrome. Chung, Yih-Lin (Taiwan ). U.S. Pat. Appl. Publ. US 2004018958 A1 29 Jan 2004,17 pp. (English). (United States of America). CODEN: USXXCO. CLASS: ICM: A61K038-16. ICS: A61K031-545; A61K009-127; A61K031-19; A61K031-165; A61K031-075. NCL: 514002000; 514557000; 514617000; 514720000; 424450000; 514570000. APPLICATION: US 2002-205738 25 Jul 2002. DOCUMENT TYPE: Patent CA Section: 1 (Pharmacology) Section cross-reference(s): 8, 63 The invention relates to a pharmaceutical compn. 58880-19-6 and 1716-12-7 are cas registry numbers of chemicals which are used as reagents here. and method for treatment of radiation cutaneous syndrome. The invention discloses administration of a therapeutically effective amt.of a histone deacetylase inhibitor,e.g. valproic acid, as method for therapy of radiation cutaneous syndrome. The compds. are capable of simultaneously stimulating epithelium regrowth, inhibiting cutaneous fibroblast proliferation, decreasing collagen deposit, suppressing fibrogenic growth factor and subsiding inflammatory cytokine, and are useful inhibiting the main features of radiation cutaneous syndrome. Results include a decrease in skin swelling, promotion of epithelium healing, and prevention of cutaneous fibrosis, ulceration and necrosis. .